Bone marrow transplantation is known to be associated with considerable morbidity and mortality. The aim of this study was to determine the influence of nutritional status and development of sick euthyroid syndrome as prognostic factors for outcome after BMT. In 100 patients who underwent transplantation the following parameters were assessed before and at day 14 and 28 after transplantation: anthropometric data (body weight, body mass index, body composition, grip strength), rapid turnover proteins transferrin and prealbumin, T4, T3, free T4, reverse T3, thyroid-stimulating hormone and thyroglobulin. Following bone marrow transplantation, 22 patients died in the short-term follow-up (group A) before day 140 after BMT, 21 patients died during further follow-up between days 140 and 365 (group B) and 57 patients survived longer than 365 days (group C). All patients experienced a significant decrease of transferrin and T3, accompanied by an increase of rT3 and rT3/T3 ratio at day 14 after BMT. At day 28 after BMT, patients in group C showed recovery from these changes with an increase of transferrin and a fall in rT3 and the rT3/T3-ratio, which was not seen in patients who died during further follow-up (groups A and B). The observed changes were independent of other prognostically relevant factors (type of disease, HLA-match, immunosuppression). Impaired nutritional status and development of a sick euthyroid syndrome, without tendency to recovery, are associated with a higher probability of fatal outcome after bone marrow transplantation and have prognostic relevance in this group of patients.
eases. However, patients have to be treated with preparative conditioning regimens including high-dose total body irradiation and chemotherapy before transplantation, and cure can only be achieved at the price of considerable morbidity and mortality.
Prognosis and survival rates in patients after BMT are determined by a variety of factors including type of underlying disease, histocompatibility between donor and recipient, age of the patient, development of graft-versus-host disease (GVHD), type and incidence of complicating infections and intensity of immunosuppression. All these factors have an important impact on short-term and long-term survival rates. 1 It has been clarified over the past several years that neoplastic, as well as chronic infectious diseases, may cause a severe wasting diathesis with negative caloric and nitrogen balance leading to death, despite the absence of a large tumor burden. 2 Survival after major abdominal surgery and cardiovascular surgery depends on the preinterventional condition and especially on the nutritional status of the patient. 3 There have been data suggesting that rapid turnover proteins can be used as prognostic indicators in cancer patients 4 and that transferrin levels can be used as a prognostic indicator in patients undergoing bone marrow transplantation. 5 The ability to accurately assess nutritional status has been improved over the past several years. [6] [7] [8] Anthropometric data including weight, body mass index and body composition 9, 10 and biochemical parameters of nutrition, such as the rapid turnover proteins transferrin, prealbumin and retinol-binding proteins can be used as sensitive markers because of their short half-life compared to albumin. 4, [11] [12] [13] Alterations of thyroid hormone parameters are frequently observed in sick patients and commonly known as nonthyroidal-illness (NTI) or sick euthyroid syndrome. 14, 15 The most common feature of NTI is the low-T3 syndrome, ie low peripheral T3 levels in the presence of normal T4 (thyroxine) and TSH (thyroid-stimulating hormone) values. 80% of the circulating T3 is derived from conversion of T4 to T3, mainly in the liver. The enzyme 5Ј-deiodinase catalyses the removal of iodine from the outer ring of T4. In sick patients a reduced 5Ј-deiodinase activity can be observed. The low-T3 syndrome is frequently observed during caloric restriction, after surgery and after myocardial infarction. 16, 18 On the other hand, an increase in reverse-T3 (rT3), generated by the inner-ring deodination of thyroxine, is observed. rT3 has no thyromimetic activity. In severely ill patients T4 concentrations also begin to fall in addition to low-T3 concentrations. This hormone constellation has been called low-T3/ low-T4 syndrome and is correlated with a bad prognosis. 19, 20 The relevance of these observations is still unclear. Typically, thyroid hormone parameters return to normal with recovery from the underlying illness.
This study was designed to assess the relevance of nutritional status and thyroid parameters before and in the short-term follow-up after BMT in order to predict patient outcome. Anthropometric parameters of nutrition (body weight, BMI, body composition, grip strength) were evaluated before BMT and in patients who survived at discharge from the hospital, 6 and 12 months after BMT. The rapid turnover proteins transferrin and prealbumin and parameters of thyroid metabolism were determined before and in the short-term follow-up every 14 days after transplantation to assess the incidence of low-T3 syndrome after BMT, and to assess the role of development of a low-T3 syndrome as a prognostic indicator of BMT.
Materials and methods

Patients
We consecutively enrolled 100 patients, 61 men and 39 women undergoing allogeneic bone marrow or peripheral blood stem cell transplantation at the Department of Bone Marrow Transplantation of the University Hospital of Essen, from September 1995 to October 1996. Exclusion criteria were thyroid disease and use of thyroid hormones or thyrostatic medication before transplantation. Indications for bone marrow transplantation were mainly CML (chronic myelogenic leukemia), AML (acute myelogenous leukemia), ALL (acute lymphoblastic leukemia) and NHL (non-Hodgkin's lymphoma). Patient characteristics including distribution of age, sex, diagnosis, type of conditioning therapy, HLA-match, number of blood product transfusions and duration of hospital stay are summarized in Table 1 .
All patients included were observed for at least 1 year after bone marrow transplantation. Forty-three patients died within the first year of transplantation, while 57 patients survived longer than 1 year after transplantation. For further analysis of prognostic factors influencing survival after BMT, patients were categorized according to clinical outcome. Group C consists of the 57 patients who survived longer than 365 days after BMT. The 43 patients who died within the first year were further classified according to date of occurrence of death. Twenty-two patients who lived less than 140 days after transplantation (mean time until death: 70 ± 37 days) were defined as group A. Group B consisted of 21 patients who died between day 140 and day 365 after transplantation (mean time until death: 222 ± 63 days). 
Bone marrow transplantation and immunosuppressive regimen
Before transplantation, patients received different chemotherapies for their underlying hematological disease. For CML, therapy usually included hydroxyurea and/or interferon-alpha, 21, 22 and for acute leukemias different wellknown and previously described higher-dose combination chemotherapy had been given. [23] [24] [25] [26] Details of the different conditioning regimens and of GVH prophylaxis have also been previously described. 27 In the majority of cases, total body irradiation was part of the pretransplant conditioning therapy; the different pretransplant conditioning regimens are summarized in Table 2 . GVHD prophylaxis with cyclosporin A and methotrexate was started at day −1. Transplantation was performed with bone marrow or peripheral blood stem cells at day 0. In patients with HLA-identical related donors without GVHD cyclosporine was tapered and discontinued at day 90 post-BMT and in HLA-mismatched or unrelated donors, 1 year after BMT. Patients with GVHD were treated with cyclosporine and corticosteroids, starting with 2 mg/kg body weight and dose escalation or reduction depending on the course of GVHD.
Parenteral nutrition was started on day −1 with 40% glucose solution, 10% amino acids solution and 20% lipid solution starting on day 5. Nutritional therapy was supplemented by water-and fat-soluble vitamins in standard doses. Calorie intake was approximately 35 kcal/kg BW/day.
Patients who never received steroids after BMT are referred as non-steroid users. In patients receiving steroids, the cumulative steroid dose (expressed in prednisone equivalents) was calculated with the help of the patient's medical record. The cumulative steroid dose/body weight was calculated dividing total cumulative steroid dose by body weight. Other medications, including cyclosporin A and mycophenolate, were documented.
Evaluation of thyroid function
Serum thyroxine (T4), serum triiodothyronine (T3), serum thyrotropin (TSH), reverse T3 (rT3), free thyroxine (fT4) were analyzed at day −10, and days 14 and 28 after transplantation. All samples for one patient were assayed in duplicate in one assay to avoid interassay variation.
T4 (normal values 58-154 nmol/l), T3 (normal values: 1.23-3.08 nmol/l) and free T4 (normal values: 10-25 pmol/l) were determined by a competitive immunoluminescence assay (ACS; Chiron Diagnostics, East Walpole, USA). TSH (normal values: 0.3-4.0 mU/l) was measured by a two site luminescence immunoassay (ACS; Chiron Diagnostics).
Reverse T3 (rT3) (normal values 0.09-0.35 ng/ml) was measured by a radioimmunoassay (Biochem Immunosystems, Freiburg, Germany); intraassay coefficient of variation (CV) was 6.5%.
Thyroglobulin (TBG) (normal values 11.3-28.9 mg/l) was measured by a radioimmunoassay (Brahms Diagnos-tika, Berlin, Germany); intraassay CV was 3%. T4/TBG ratio was calculated by the formula: T4 (nmol/l)/TBG (mg/l) × 12.87. rT3/T3 ratio was calculated by the formula: rT3 (ng/ml) × 15.36/T3 (mmol/l).
Evaluation of nutritional status
Transferrin and prealbumin were analyzed at day −10 and days 14 and 28 after transplantation. BMI, as the generally acknowledged parameter of body weight, was calculated according to Hannan 
Assessment of total body composition
Total body composition was measured by dual energy Xray absorptiometry (DEXA) (Lunar DPX-L, Madison, WI, USA) as a total body scan. The total body is composed of fat mass (20-50% of total body weight), lean mass (muscle, fluid, connective tissue) (45-75% of total body weight) and bone mineral (5% of total body weight). 28 Percentage muscle mass is the lean mass related to total body weight in %.
Body composition was analyzed before transplantation, at time of discharge from the hospital and 6 and 12 months after transplantation. Definition of groups A, B and C see Table 2 .
Assessment of grip strength
Grip strength was measured by a vigorimeter (Martin, Tuttlingen, Germany). Patients were required to press a pressure ball with the dominant hand three times. The highest value expressed in kilo-Pascals was used to quantitate grip strength. Grip strength gives an indirect measure of muscle strength. 29 
Statistical methods
Results are expressed as the mean ± 1 s.d. of the mean. For normally distributed values the Student's t-test and ANOVA were used to compare the within-group difference for follow-up data and the differences between groups.
Results
Characterization of the study population
Characteristics of the 100 patients included in the study are summarized in Table 1 . The course of patients who survived was characterized by fewer complications, expressed by a smaller number of transfusions and lower doses of steroids. Incidence and severity of acute GVHD were not analyzed separately, but steroid doses, typically started for GVHD, can be used to approximate the occurrence and degree of acute GVHD. Patients in group A had received the largest doses of steroids, and patients in group C smallest doses. The subgroups were comparable for disease leading to transplantation, age and sex distribution, type of transplant and pretransplant conditioning therapy.
Relation between nutritional status and outcome after BMT
Transferrin and prealbumin levels during short-term followup after BMT are summarized in Table 3 . Transferrin levels decreased significantly from day 0 to day 14 after transplantation in all groups. Patients in groups B and C showed a tendency to normalize transferrin levels at day 28, while patients in group A with the worst prognosis did not show this tendency. The difference in transferrin levels between groups A and C was statistically significant before BMT (P = 0.03) and at day 28 after BMT (P = 0.001), but not at day 14 after BMT. The difference in transferrin levels between group B and C was statistically significant before (P = 0.0001) and at day 28 (P = 0.0069), but not at day 14 after transplantation. There was no significant difference in transferrin levels between groups A and B at any time. Prealbumin levels were below normal (Ͻ25 ng/ml) in 13 of 93 (14%) patients before transplantation, 59 of 79 (75%) at day 14, 16 of 56 (28%) and eight of 25 (32%) after transplantation. Prealbumin values also decreased to lowest values at day 14, but had already normalized back to almost pretransplant values 28 days after BMT. Prealbumin levels were not suitable for differentiation of different prognostic groups.
Anthropometric status was analyzed in all patients before transplantation and data are summarized in Table 4 . Groups A, B and C were comparable for body weight and muscle mass before BMT, and patients in group A showed a significantly decreased grip strength compared to group C (P = 0.05). Before transplantation, 8% were underweight (BMI Ͻ20 kg/m 2 ), 43% of normal weight (BMI 20-25 kg/m 2 ), 36% were overweight (BMI 25-30 kg/m 2 ) and 13% were obese (BMI Ͼ30 kg/m 2 ). All patients in groups B and C were reassessed at discharge. There was significant loss of body weight in all patients at discharge from the transplant unit (−7.1 ± 9 kg (group B) vs −6.3 ± 6.6 kg (group C), P = NS). Loss of body weight was preferentially muscle mass (−7.2 ± 5 kg (group B) vs −5.5 ± 5.2 kg (group C), P = NS), while fat mass increased (+1.3 ± 0.7 kg (group B) vs +0.3 ± 3.6 kg (group C), P = NS).
Patients in group C were reassessed 6 and 12 months after BMT. Total body weight, body composition and grip strength had not returned to pretransplant values, at 6 Table 4 Assessment of anthropometric status in patients before and after bone marrow transplantation subanalyzed according to outcome Definition of groups A, B and C see Table 2 .
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months or 12 months after BMT, indicating the longlongstanding alterations induced by BMT. Table 3 and Figure 1 summarize the parameters of thyroid metabolism measured before transplantation and in the short-term follow-up at day 14 and 28 after transplantation. Before transplantation, all patients showed normal levels of total T4, T3, fT4, rT3, TSH and rT3/T3 ratio. There was a significant difference between groups A and B for T3 (P = 0.04) and TSH (P = 0.02), and between A and C for TSH (P = 0.03).
Relation between incidence of low T3 syndrome and outcome after transplantation
At day 14 after transplantation, T3 and TSH values dropped significantly in all patients, whereas the rT3 and rT3/T3 ratio increased significantly. At day 14 patients are at the aplasia nadir. There was a significant difference between groups A and C for T3 (P = 0.02), rT3 (P = 0.02) and rt3/t3 ratio (P = 0.0022).
Two of 14 (14%) patients in group A, one of 13 (8%) patients in group B and two of 49 (4%) patients in group C showed T4 values below lower normal limits (Ͻ58 nmol/l) at day 14. Four of 14 (28%) in group A, two of 13 (15%) in group B and no patient in group C showed T3 values below the normal limit (Ͻ1.23 nmol/l) at day 14. At day 28 after transplantation, the majority of patients have engrafted and passed the period of cell aplasia. Patients in group C showed a recovery with a rise of T4, T3 and TSH and a drop of rT3 and rT3/T3 ratio. In contrast, patients in groups A and B did not show this recovery; their T4 and T3 values continued to decrease and rT3 and rT3/T3-ratios showed a further increase. There was a significant difference between groups A and C for T4 (P = 0.0045), T3 (P = 0.001), rT3 (P = 0.0014) and rT3/T3 ratio (P = 0.0001). There was a significant difference between groups B and C for rT3 (P = 0.0003) and for the rT3/T3 ratio (P = 0.0002).
Four of nine (44%) patients in group A, no patient in group B and one of 35 (3%) patients in group C showed T4 values below lower normal limits (Ͻ58 nmol/l) at day 28. 55% patients in group A, 30% patients in group B and 17% patients in group C showed T3 values below normal limits (Ͻ1.23 nmol/l) at day 28.
The T4/TBG-ratio was stable over time indicating that there were no significant changes in TBG concentrations. There were no differences during follow-up within a group or between groups.
Influence of the use of corticosteroids on thyroid metabolism
To analyze the influence of corticosteroids on thyroid metabolism after BMT, we divided patients into those who did not receive corticosteroids and those who did during their stay in the transplant unit. The indication for steroid therapy was the development of acute GVHD. Groups were comparable for age, sex and disease leading to BMT. Patients who did not receive corticosteroids obviously had significantly shorter hospital stays. The steroid users were comparable with the 'non-users' concerning thyroid metabolism before transplantation and at day 14. At day 14 neither patient groups had taken steroids. Steroid therapy for acute GVHD is typically started around day 20 or later. At day 28 patients who had to take steroids showed a decrease in T4 and T3 and rise in rT3 and rT3/T3 ratio characteristic for the development of low T3 syndrome. In contrast, the patients who did not have to take steroids did not show this pattern. Both groups showed a fall in TSH irrespective of steroid administration.
Discussion
Malnutrition is a common finding in patients with advanced renal, liver or heart dysfunction before organ transplantation 30 and complicates transplantation surgery by increasing morbidity and mortality. We showed low levels of transferrin before BMT to be an indicator for risk of early death after transplantation.
Loss of body mass after transplantation was mainly caused by reduced muscle mass, expressed by the change in body composition, with decreasing lean mass and decrease in grip strength. Patients who survived for more than 1 year after bone marrow transplantation did not regain their pre-transplant physical condition within 1 year after BMT, still showing decreased muscle mass and grip strength. Wehmann et al 31 evaluated T4, T3 and TSH concentrations following BMT and found a decrease in thyroid-hormone parameters and NTI in nearly all patients. However the onset of these alterations was not characteristic and the relevance of NTI as a prognostic factor in these patients was not evaluated. Vexiau et al 32 studied the incidence of thyroid abnormalities 3 months after BMT and found that the 30-month projected survival time was 83% for patients without and 49% for patients with abnormalities. We designed our study to evaluate very short-term changes in thyroid metabolism within the first 28 days after BMT.
Generally, the period after BMT can be divided into two periods with regard to thyroid function:
(1) Within 2 weeks after BMT, a decrease in TSH and T3
concentrations and an increase in reverse-T3 is observed in all patients undergoing BMT, irrespective of the outcome. Thus, these alterations are an effect of BMT per se. Nevertheless, the increase in reverse-T3 and the decrease in T3 is more pronounced in those patients who eventually died. (2) Four weeks after BMT thyroid hormone parameters had normalized in those patients who had an uneventful course, and returned to pretransplant values. However, patients with a fatal outcome demonstrated significantly lower T4 and T3 concentrations at that time. In patients who died before day 140 after BMT, 54% had T3 levels below normal and 46% had T4 values below normal, whereas only 17 and 4% respectively, of the patients who survived showed such a decrease in T4 and T3 levels. These results emphasize the prognostic importance of low-T4-T3 syndrome in the period after BMT that has also been shown in various other diseases. 19, 20 Free-T4 concentrations, as in our study, are usually normal in patients with NTI. 14, 33 In our study the degree of T4 to T3 conversion inhibition and subsequent decrease in T3 seems to be a good discriminator with respect to mortality after BMT and may therefore be valuable in the clinical setting. The most specific parameter seems to be the rT3/T3 ratio, which was very high in those patients who died (rT3/T3 ratio Ͼ8, with a specifity of 98%). As reverse T3 is not determined on a routine basis, the clinician may rely on total-T4 and T3 concentrations as mentioned above.
Among the various drugs known to influence thyroidhormone parameters, corticosteroids must be considered in patients undergoing BMT. 34 The indication for the use of corticosteroids in our patients was acute GVHD. Both groups of patients, those taking or not taking corticosteroids, patients with and without GVHD, were comparable with respect to thyroid-hormone parameters before and up to 2 weeks after BMT. However, on day 28 T4 and TBG concentrations were lower, and rT3 concentrations higher in patients receiving steroids. This reflects the fact that patients who required steroids were sicker than those not receiving steroids and that steroids inhibit T4 to T3 conversion and reduce TBG concentration. 34, 35 Glucocorticoids are known to inhibit TSH secretion in a dose-dependent manner. 36, 37 Surprisingly, in our patients TSH did not differ between the two groups either receiving corticosteroids or not. In Wehmann's study 31 TSH was also not influenced by the use of steroids.
In summary, low transferrin levels as a sign of malnutrition are seen most commonly in patients with a fatal outcome after BMT. Further studies should show whether patients with low transferrin levels before transplantation profit from prophylactic nutritional support in addition to the established parenteral nutrition during the transplantation procedure itself.
The changes in body composition with preferential loss of muscle mass observed after BMT do not resolve until 1 year after BMT. Further studies may show whether post-BMT patients will profit from special exercise training programs to prevent further loss of body weight and especially muscle mass. This may eventually ameliorate the overall outcome of these patients.
The immediate period after BMT is associated with low-T3 syndrome. While patients with an uneventful course return to pre-transplant thyroid values within 4 weeks, patients who will die during further follow-up do not recover from the observed thyroid abnormalities. We find it very interesting that differences in response to the stress of BMT at day 28 after BMT can discriminate between different prognostic groups. In particular, the development of low-T3-low T4 syndrome is typical of fatal outcome shortly after BMT. The degree of T4 to T3 conversion inhibition as indicated by the magnitude of the reverse-T3/ T3 ratio seems to be the most specific predictor in terms of mortality. The influence of steroids on TSH secretion pattern after BMT seems negligible.
